Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 300.00
Bid: 297.00
Ask: 304.00
Change: 0.00 (0.00%)
Spread: 7.00 (2.357%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 300.00
APTD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preliminary Results

26 Feb 2014 07:00

RNS Number : 9201A
Microgen PLC
26 February 2014
 



26 February 2014

MICROGENplc ("Microgen")

Audited Preliminary Results for the Year Ended

31 December 2013

Microgen reports its audited preliminary results for the year ended 31 December 2013.

SUMMARY

· Completion in October 2013 of Strategic Review with Microgen becoming the corporate parent of a series of technology businesses and strategic investments. The Group returned cash to shareholders over the prior 5 year period equivalent to 130% of the October 2008 market capitalisation.

· The Aptitude Software business reports annual software licence and recurring revenue growth of 9% to £7.9 million (2012: £7.2 million) representing 54% of its revenue (2012: 44%). As anticipated and consistent with the strategy, consultancy revenues declined to £6.8 million (2012: £8.8 million). New sales partnership launched.

· The Financial Systems business reports wealth management revenue growth of 7% to £8.0 million (2012: £7.5 million) representing 53% of its revenue (2012: 47%). In line with expectations, Financial Systems' other product revenues reduced to £7.1 million (2012: £8.5 million).

· Group adjusted operating profit in line with expectations at £9.1 million (2012: £9.1 million)*. Group operating profit on a statutory basis of £8.7 million (2012: £9.0 million).

· Adjusted earnings per share marginally lower at 8.3 pence (2012: 8.5 pence) following changes to the capital structure and resulting reduced net interest income.

· Strong balance sheet with cash of £40.2 million (2012: £32.1 million). Net funds of £20.9 million (2012: £32.1 million) following the return of £17.0 million in the year to shareholders by way of tender offer and dividends.

· Proposed final dividend of 2.2 pence per share (2013: 2.2 pence) representing a full year dividend of 3.3 pence (2012: 3.3 pence) in addition to the special dividend paid in May 2013 of 5.2 pence per share.

 

Contacts

Martyn Ratcliffe, Executive Chairman 020-7496-8100

Philip Wood, Group Finance Director

 

Lucy Delaney, FTI Consulting 020-7269-7208

 

* Throughout this statement adjusted operating profit and margin excludes exceptional and other items, unless stated to the contrary.

 

MICROGEN plc ("Microgen")

Audited Preliminary Results for the Year ended 31 December 2013

Chairman's Statement and Group Strategy

Microgen maintained a resilient financial performance in 2013. The year was significant due to the Board's extensive review of the strategies of the Group and its businesses ("Strategic Review" or "Review"). The timing of the Review coincided with achieving the milestone of returning in cash the Group's market capitalisation to shareholders over the 5 year period following the completion of the previous review in October 2008. The £10 million tender offer announced as one of the outcomes of the Review brought the total cash returned to shareholders over the 5 year period to 130% of the October 2008 market capitalisation. The detail of the Strategic Review was announced on 29 October 2013 and is incorporated in this statement by reference.

The Strategic Review detailed that the Group strategy is to "Acquire, Enhance and Realise Value" for Microgen shareholders. As a result Microgen plc is now the corporate parent of a series of technology businesses and strategic investments, operated as independent business units. Reflecting the new organisational structure, reports on the Group's existing businesses, Aptitude Software and Financial Systems, are provided by the respective Managing Directors. Pursuant to the Strategic Review, investment is being significantly increased in the Aptitude Software business in order to pursue the developing Big Data opportunity. In parallel, the Financial Systems business is focussing resources on the growing wealth management sector and delivered a substantial increase in return on capital employed following the change in capital structure.

Despite a period of strategic evolution, in aggregate, the Group reports adjusted operating profit in line with expectations and with the prior year (throughout this statement adjusted operating profit and margin excludes exceptional and other items, unless stated to the contrary). Pursuant to this performance the Board is recommending a final dividend of 2.2 pence per share (2012: 2.2 pence), representing a full year dividend of 3.3 pence (2012: 3.3 pence) in addition to the special dividend of 5.2 pence paid in May 2013. Subject to shareholder approval, the proposed final dividend will be payable on 27 May 2014 to shareholders on the register at the close of business on 25 April 2014.

Microgen is continuously identifying and appraising technology businesses and strategic investments which the Board believes, based on the Group's capabilities and technologies, may benefit from being operated as an independent business unit under Microgen's stewardship. Consistent with the scope set out in the Strategic Review announcement, the businesses and investments appraised to date have been predominantly UK based across a broad technology spectrum.

During 2013, Microgen returned £17.0 million of cash to shareholders through dividends and the tender offer which completed in December. The Group's balance sheet, with cash of £40.2 million at 31 December 2013 (2012: £32.1 million) and net funds of £20.9 million (2012: £32.1 million), still provides the Group with the cash resources to be a credible acquirer although the Board would seek additional support from shareholders if appropriate. However, the Board will maintain its prudent approach and there can be no certainty that any material acquisition will be completed.

Martyn Ratcliffe

Executive Chairman

 

 

Aptitude Software Report

The Aptitude Software business provides enterprise level application products and solutions, typically where customers require very rapid processing of very high volume (often referred to as "Big Data") complex, business event-driven transactions. The Aptitude software and associated applications have been, and continue to be, developed at the Aptitude Technology Centre in Wroclaw, Poland. The cost of this development is expensed as incurred on an annual basis. The business generates revenue from this software through a combination of annual licence fees, software maintenance and support, professional services and, to a lesser extent, initial licence fees.

The Strategic Review reaffirmed the Group's preferred strategy of annual software licencing, producing recurring revenues, as the right approach to value creation. As such, the Board's objective of increasing licence revenue, both in absolute terms and as a proportion of revenue, is the leading performance metric for the business. (Recurring revenue includes annual licence fees, software maintenance and support).

Benefitting from both new business sales and growth from the existing client base, revenue from annual software licences and other recurring revenue grew by 9% to £7.9 million (2012: £7.2 million) and now represents 54% of revenue (2012: 44%). Whilst not materially benefitting 2013 due to the Group's conservative revenue recognition policy, a significant new European client was contracted in December 2013 with a North American opportunity in the final stages of contracting.

The number of consultants deployed during 2013 was broadly flat, although this is a reduction on 2012 particularly in the first half of the year, when customer budgetary constraints had a material impact. However, the future growth of consultancy revenue is not a strategic objective of the business, reflecting the change in emphasis towards software revenues to align with the greater potential for shareholder value-creation. As a result, despite broadly consistent services revenue throughout 2013, the impact of the decline in 2012 has led to services revenue reducing to £6.8 million compared to £8.8 million in the prior year.

Correspondingly, overall reported revenue for the business was £14.7 million (2012: £16.3 million). Nevertheless, strong operating margins of 19% (2012: 18%) delivered an operating profit of £2.8 million (2012: £2.9 million) while maintaining investment in research and development at £3.5 million (2012: £3.5 million) and continuing to expense as incurred all research and development costs.

Following the Strategic Review the Board has approved an increase in investment in order to pursue the potential from the Big Data market opportunity at a level such that the business remains profitable and cash flow positive. Details of the areas of investment were described in the Strategic Review including product development of a Hadoop interface which will expand the multi-platform Aptitude offering. Costs incurred in 2013 related to these investments have not been significant.

In 2014, the Aptitude Software business has commenced a sales partnership with IBM, further developing the indirect sales channel to complement the established direct sales force. In addition, opportunities have been identified in a number of new sectors which will benefit from the capabilities of the Aptitude software. In summary, 2013 realigned the strategy for the Aptitude Software business. While the tangible results from the changes will take time, the significant new European client contracted in December 2013, the launch of the IBM sales partnership and the new product development activities provide an exciting opportunity for the future.

Tom Crawford

Managing Director, Aptitude Software

 

 

Financial Systems Report

The Financial Systems business has a well-established customer base with an increasing focus on the wealth management sector. Revenues are generated through a combination of annual licence fees, software maintenance and support, professional services and, to a lesser extent, initial licence fees. The Strategic Review concluded that the business should focus on increasing the proportion of revenue derived from the wealth management sector through both organic growth and add-on acquisitions while continuing to explore opportunities in other financial services sectors.

During 2013 revenue from wealth management products grew 7% to £8.0 million (2012: £7.5 million) and now represents 53% (2012: 47%) of revenue. The leading wealth management product, 5Series, continues to be well received by the market with adoption increasing in line with expectations. In 2013, the business contracted with a major US bank and is currently in the process of implementing the largest ever 5Series deployment. The other more mature product categories, and non-financial services offerings in particular, continued to decline, as anticipated, with revenue in 2013 of £7.1 million (2012: £8.5 million).

Overall reported revenue was £15.1 million (2012: £16.0 million), in line with the Board's expectations. Recurring revenues account for 79% (2012: 78%) of the revenue, with 28% of revenue being generated by its top 5 clients (2012: 28%). Benefitting from continued tight cost control, the business reported strong adjusted operating profits of £8.1 million (2012: £8.4 million) representing an adjusted operating margin of 54% in 2013 (2012: 53%). The expenditure on research, development and support activities in 2013 was £2.2 million (2012: £2.2 million) the costs of which have been, and continue to be, expensed on an annual basis with no capitalisation.

The Strategic Review provided the catalyst for the Board to consider the capital structure of the Financial Systems business and the opportunity for Microgen to manage the business using a more efficient capital model. As a result the Review announced the agreement of a £20 million bank loan, secured solely against the Financial Systems business at a very competitive interest rate, reflecting the consistently strong cash flow from the business. £5 million of the received funds were retained by the business to fund add-on acquisitions with £15 million distributed to Microgen plc. The loan is repayable over five years with an annual capital repayment of £3 million and the remainder at the end of the period. The interest rate has been fixed by an appropriate financial instrument at 3.24% over the five year period. Operating covenants are limited to the performance of the Financial Systems business based on net debt leverage, interest cover and a minimum cash balance of £3 million being held within the business. Furthermore, in the event of a default by the Financial Systems business, Microgen plc has the option, but not the obligation, to remedy. Following the agreement of this loan and the capital reorganisation of the business during the year, the Return on Capital Employed ("ROCE") for 2013 is 30% (2012: 18%). (For the purposes of calculating ROCE, capital is defined as being the average of the consolidated net assets of the business at the beginning and end of each year). The interest cost in 2013, representing only the two months since the loan was advanced on 29 October 2013, was £0.1 million. The loan outstanding at 31 December 2013 was £19.3 million (2012: £nil).

In pursuing the major strategic objective of the business, namely to increase the proportion of revenues generated from the wealth management sector, the business has continued to identify and appraise a number of add-on acquisitions. However, the Board remains prudent and there can be no certainty that any acquisitions will be completed in the near future. Meanwhile, the existing Financial Systems business benefits from its high level of recurring revenues and the business is confident the adoption of the 5Series wealth management product will continue to progress in 2014.

Simon Baines

Managing Director, Financial Systems

 

 

Group Financial Performance and Finance Director's Report

Value to shareholders is derived from the aggregation of the performance of the operating businesses. The Group results are therefore provided for statutory purposes but in isolation provide minimal additional perspective.

Revenue for the year ended 31 December 2013 was £29.8 million (2012: £32.3 million) producing an adjusted operating profit in line with both expectations and the prior year of £9.1 million (2012: £9.1 million). Operating profit on a statutory basis was £8.7 million (2012: £9.0 million). The Group reported a profit for the year attributable to equity shareholders of £6.4 million (2012: £6.9 million). In accordance with IFRS, the Board has continued to determine that all internal research and development costs are expensed as incurred and therefore the Group has no capitalisation of development expenditure. The overall group expenditure on research, development and support activities in 2013 was £5.7 million (2012: £5.7 million). Despite the reduction in revenue, adjusted operating margins increased to 30% (2012: 28%) due to the Group's conservative operational approach. This has been achieved by the growth in the proportion of the Group's higher margin annual software licences and other recurring revenues together with a reduction in the Group's overheads. Headcount at 31 December 2013 was 228 including contractors and associates (31 December 2012: 238).

Whilst the majority of the Group's revenue is invoiced in Pounds Sterling, £4.1 million of the revenue was invoiced in US Dollars at an average exchange rate of 1.56 (2012: £2.3 million at 1.59) and £1.3 million was invoiced in South African Rand at an average exchange rate of 15.22 (2012: £1.5 million at 13.04). It is Microgen's policy to hedge foreign exchange cash flows once the size and timing of transactions can be predicted with sufficient certainty. To date only the costs in relation to the Aptitude Technology Centre in Poland are hedged but in light of the changes in the business the Board continue to monitor whether it is appropriate to hedge other currencies.

Pursuant to the shareholder approval on 18 November 2013, options in respect of 5.5 million ordinary shares were issued to directors and management. A profit and loss charge of £0.1 million was incurred in the period in respect of these options and is included in the total exceptional and other item costs of £0.4 million together with costs in respect of the arrangement of the £20.0 million loan entered into by the Financial Systems business in the year, details of which are summarised in the Financial Systems Report. The total tax charge of £2.3 million (2012: £2.2 million) represents 26% of the Group's profit before tax (2012: 24%). The Group's tax charge benefitted from the recognition of £0.1 million (2012: £0.2 million) tax losses in the year. The deferred tax asset in relation to taxable trading losses represents only £0.1 million (2012: £0.2 million) of the overall deferred tax asset of £0.8 million (2012: £1.0 million) with short term timing differences representing the principal component at £0.3 million (2012: £0.4 million). Adjusted earnings per share for the year ended 31 December 2013 was 8.3 pence (2012: 8.5 pence).

The Group completed a £10.0 million tender offer in December 2013 purchasing 8,130,075 ordinary shares. In addition, ordinary dividends paid during 2013 totalled £2.7 million with a further £4.3 million returned to shareholders by way of a special dividend. The total returned to shareholders in 2013 was £17.0 million. Following the agreement of the loan for the Financial Systems business of £20.0 million and the above returns to shareholders, the Group continues to have a strong balance sheet with net assets at 31 December 2013 of £54.4 million (2012: £64.7 million), including cash at 31 December 2013 of £40.2 million (2012: £32.1 million), and net funds at 31 December 2013 of £20.9 million (2012: £32.1 million). Continuing to be a focus of the Group, cash conversion (measured by cash generated from operations as a percentage of operating profit) was 93% in the year (2012: 115%).

Philip Wood

Group Finance Director

 

Group Income Statement

for the year ended 31 December 2013

 

Year Ended 31 Dec 2013

 

Year Ended 31 Dec 2012

 

 

Notes

Before

exceptional

and other

items

amortisation

 

Exceptional

and other

items

 

 

 

Total

Before

exceptional

and other

items

 

Exceptional

and other

items

 

 

 

Total

£000

£000

£000

£000

£000

£000

Revenue

1

29,824

-

29,824

32,318

-

32,318

Operating costs

1

(20,755)

(381)

(21,136)

(23,187)

(118)

(23,305)

Operating profit

9,069

(381)

8,688

9,131

(118)

9,013

Finance income

119

-

119

174

-

174

Finance cost

(119)

-

(119)

-

-

-

Net finance income

-

-

-

174

-

174

Profit before income tax

9,069

(381)

8,688

9,305

(118)

9,187

Income tax expense

2

(2,250)

(2,238)

Profit for the year

6,438

6,949

Earnings per share

Basic

3

7.9p

8.5p

Diluted

3

7.7p

8.3p

 

 

group statement of comprehensive income

For the year ended 31 December 2013

 

 

 

Year ended

31 Dec 2013

Year ended

31 Dec 2012

 

£000

£000

Profit for the year

6,438

6,949

Other comprehensive income

 

 

Items that will or may be reclassified to profit or loss:

 

 

Fair value (loss)/ gain on hedged financial instruments

(7)

409

Currency translation difference

75

80

Other comprehensive income for the year, net of tax

68

489

Total comprehensive income for the year

6,506

7,438

 

 

Group Balance Sheet

For the year ended 31 December 2013

 

 

 

As at

31 Dec 2013

As at

31 Dec 2012

 

Notes

£000

£000

ASSETS

 

 

 

Non-current assets

 

 

 

Property, plant and equipment

 

5,022

5,391

Goodwill

 

41,774

41,774

Deferred income tax assets

 

752

1,041

 

 

47,548

48,206

Current assets

 

 

 

Trade and other receivables

5

5,049

3,163

Financial assets - derivative financial instruments

 

94

69

Cash and cash equivalents

 

40,200

32,134

 

 

45,343

35,366

Total assets

 

92,891

83,572

 

 

 

 

LIABILITIES

 

 

 

Current liabilities

 

 

 

Financial liabilities

 

 

 

 

 

 

 

-borrowings

7

(3,000)

-

- derivative financial instruments

 

(47)

(15)

Trade and other payables

6

(18,186)

(17,845)

Current income tax liabilities

 

(701)

(742)

Provisions for other liabilities and charges

8

(33)

(42)

 

 

(21,967)

(18,644)

Net current assets

 

23,376

16,722

 

 

 

 

Non current liabilities

 

 

 

Financial liabilities - borrowings

7

(16,250)

-

Provisions for other liabilities and charges

8

(269)

(256)

 

 

(16,519)

(256)

NET ASSETS

 

54,405

64,672

 

 

 

 

SHAREHOLDERS' EQUITY

 

 

 

Share capital

9

3,724

4,078

Share premium account

 

12,037

11,885

Capital redemption reserve

 

1,558

1,152

Other reserves

 

37,021

37,028

Retained earnings

 

65

10,529

TOTAL EQUITY

 

54,405

64,672

 

 

Group Statement of changes in shareholders' equity

for the Year Ended 31 December 2013

 

 

 

 

 

 

Share capital

 

£000

 

Share premium

 

£000

 

Retained earnings

 

£000

 

Capital redemption reserve

£000

 

 

Other reserves

 

£000

 

Total

equity

 

£000

At 1 January 2013

 

4,078

11,885

10,529

1,152

37,028

64,672

Profit for the year

 

-

-

6,438

-

-

6,438

Cash flow hedges - net fair value losses in the year

 

-

-

-

-

(7)

(7)

Exchange rate adjustments

 

-

-

75

-

-

75

Total comprehensive income for the year

 

-

-

6,513

-

(7)

6,506

Shares issued under share option schemes

 

52

152

-

-

-

204

Own shares purchased and cancelled

 

(406)

-

(10,269)

406

-

(10,269)

Share options - value of employee service

 

-

-

157

-

-

157

Deferred tax on financial instruments

 

 

-

-

9

-

-

9

Deferred tax on share options

 

-

-

7

-

-

7

Corporation tax on share options

 

-

-

135

-

-

135

Dividends to equity holders of the company

 

-

-

(7,016)

-

-

(7,016)

Total Contributions by and distributions to owners of the company recognised directly in equity income

 

(354)

152

(16,977)

406

-

(16,773)

At 31 December 2013

 

3,724

12,037

65

1,558

37,021

54,405

 

 

Group Cash Flow Statement

for the Year Ended 31 December 2013

 

 

 

 

 

 

Year ended

Year ended

 

 

31 Dec 2013

31 Dec 2012

 

Notes

£000

£000

Cash flows from operating activities

 

 

 

Cash generated from operations

10

8,103

10,348

Interest paid

 

(119)

-

Income tax paid

 

(1,728)

(2,023)

Net cash flows generated from operating activities

 

6,256

8,325

 

 

 

 

Cash flows from investing activities

 

 

 

Purchase of property, plant and equipment

 

(427)

(624)

Interest received

 

119

174

Net cash used in investing activities

 

(308)

(450)

 

 

 

 

Cash flows from financing activities

 

 

 

Proceeds from bank loan

 

20,000

-

Net proceeds from issuance of ordinary share capital

 

204

59

Dividends paid to company's shareholders

4

(7,016)

(2,691)

Repayment of loan

 

(750)

-

Purchase of own shares

 

(10,269)

(146)

Net cash generated from/ (used in) financing activities

 

2,169

(2,778)

 

 

 

 

Net increase in cash and cash equivalents

 

8,117

5,097

Cash, cash equivalents and bank overdrafts at beginning of year

 

32,134

26,971

Exchange rate (losses)/ gains on cash and cash equivalents

 

(51)

66

Cash and cash equivalents at end of year

 

40,200

32,134

Notes to the Audited preliminary results for the year ended 31 December 2013

 

1. Segmental analysis

 

Business segments

 

The Board has determined the operating segments based on the reports it receives from management to make strategic decisions. 

 

The segmental analysis is split into Aptitude Software and Financial Systems operating businesses.

The principal activity of the Group throughout 2012 and 2013 is the provision of IT services and solutions, including software based activity generating the majority of its revenue from software licences, maintenance, support, funded development and related consultancy. 

 

The operating businesses are allocated central function costs in arriving at operating profit/(loss). Group overhead costs are not allocated into the operating businesses as the Board believes that these relate to Group activities as opposed to the operating businesses.

 

1 (a) Revenue and operating profit by operating business

 

 

Year ended 31 December 2013

 

 

 

Aptitude Software

Financial Systems

 

 

Group

 

 

Total

£000

£000

£000

£000

Revenue

14,676

15,148

-

29,824

Operating costs

(11,839)

(7,042)

-

(18,881)

Operating profit before Group overheads 

2,837

8,106

-

10,943

Unallocated Group overheads

(1,874)

(1,874)

Operating profit before exceptional and other items

9,069

Exceptional and other items

-

(285)

(96)

(381)

Operating profit/(loss)

2,837

7,821

(1,970)

8,688

Net finance income

-

Profit before tax

8,688

Income tax expense

(2,250)

Profit for the year

6,438

 

 

 

Year ended 31 December 2012

 

 

 

Aptitude Software

Financial Systems

 

 

Group

 

 

Total

£000

£000

£000

£000

Revenue

16,316

16,002

-

32,318

Operating costs

(13,388)

(7,588)

-

(20,976)

Operating profit before Group overheads 

2,928

8,414

-

11,342

Unallocated Group overheads

(2,211)

(2,211)

Operating profit before exceptional and other items

9,131

Exceptional and other items

-

(118)

-

(118)

Operating profit/ (loss)

2,928

8,296

(2,211)

9,013

Net finance income

174

Profit before tax

9,187

Income tax expense

(2,238)

Profit for the year

6,949

 

1(b) Geographical analysis

 

The Group has two geographical segments for reporting purposes, the United Kingdom & Ireland and the Rest of the World.

 

The following table provides an analysis of the Group's sales by origin and by destination.

 

 

Sales revenue by origin

Sales revenue by destination

 

Year ended

Year ended

Year ended

Year ended

 

31 Dec 2013

31 Dec 2012

31 Dec 2013

31 Dec 2012

 

£000

£000

£000

£000

United Kingdom and Ireland

19,686

23,696

11,666

16,157

Rest of World

10,138

8,622

18,158

16,161

 

29,824

32,318

29,824

32,318

 

2. Income tax expense

 

 

Year ended

Year ended

 

31 Dec 2013

31 Dec 2012

Analysis of charge in the year

£000

£000

Current tax:

 

 

- current year charge

(1,860)

(1,973)

- prior year charge

(143)

(71)

 

(2,003)

(2,044)

Deferred tax:

 

 

- current year charge

(327)

(139)

- prior year credit/(charge)

80

(55)

 

(247)

(194)

Income tax expense

(2,250)

(2,238)

 

 

The total tax charge of £2,250,000 (2012: £2,238,000) on continuing operations represents 25.9% (2012: 24.4%) of the Group's profit before tax of £8,688,000 (2012: £9,187,000). 

 

After adjusting for the change in tax rates, prior year tax charges and exceptional and other items, the tax charge for the year of £2,286,000 (2012: £2,319,000) represents 25.21% of the profit before exceptional and other items (2012: 25.23%) which is the tax rate used for calculating the adjusted earnings per share.

 

At the balance sheet date, the Group has unused tax losses of £6,797,000 (2012: £7,606,000) available to offset against future profits. A deferred tax asset has been recognised in respect of £484,000 (2012: £790,000) of such losses which is the maximum the Group anticipates being able to utilise in the year ending 31 December 2014. No deferred tax asset has been recognised in respect of the remaining £6,313,000 (2012: £6,816,000) due to the unpredictability of future profit streams.

 

The difference between the total tax charge and the amount calculated by applying the effective United Kingdom corporation tax rate of 23.25% (2012: 24.5%) to the profit on ordinary activities before tax is as follows:

 

 

Year ended

Year ended

 

31 Dec 2013

31 Dec 2012

 

 

 

 

£000

£000

Profit on ordinary activities before tax

8,688

9,187

 

 

 

Tax at the UK corporation tax rate of 23.25% (2012: 24.5%)

(2,020)

(2,251)

 

 

 

Effects of:

 

 

Adjustment to tax in respect of prior period

(63)

(126)

Adjustment in respect of foreign tax rates

(63)

7

Foreign exchange gains on intercompany balances

(111)

(42)

Research and development tax credit

10

135

Expenses not deductible for tax purposes

 

 

- Share based payment expenses

(51)

(89)

- Other

(18)

(58)

Changes in UK Corporation Tax Rates

 

(55)

(20)

Recognition of tax losses

121

206

Total taxation

(2,250)

(2,238)

 

3. Earnings per share

 

To provide an indication of the underlying operating performance per share, the adjusted profit after tax figure shown below excludes exceptional and other items and has a tax charge using the effective rate of 25.21%

 (2012: 25.23%)

 

 

Year ended

Year ended

 

31 Dec 2013

31 Dec 2012

 

£000

£000

Profit on ordinary activities before tax and intangibles amortisation

9,069

9,305

Tax charge at a rate of 25.21% (2012: 25.23%)

(2,286)

(2,348)

Adjusted profit on ordinary activities after tax

6,783

6,957

Prior years' tax charge

(63)

(126)

Exceptional and other items net of tax

(292)

(88)

Foreign exchange gains on intercompany balances tax charge

(111)

-

Recognition of tax losses

121

206

Profit on ordinary activities after tax

6,438

6,949

 

 

2013

Number

(thousands)

2012

Number

( thousands)

 

Weighted average number of shares

81,649

81,572

Effect of dilutive share options

1,535

1,873

 

83,184

83,445

 

 

2013

Basic

EPS

2013

Diluted

EPS

 

pence

pence

 

Earnings per share

7.9

7.7

Exceptional and other items net of tax

0.3

0.3

Prior years' tax charge

0.1

0.1

Foreign exchange gains on intercompany balances tax charge

0.1

0.1

Tax losses recognised

(0.1)

(0.1)

Adjusted earnings per share

8.3

8.1

 

Adjusted earnings per share are calculated using adjusted profit after tax.

 

4. Dividends

 

 

2013 pence per share

2012 pence per share

2013

£000

2012

£000

Dividends paid:

 

 

 

 

Interim dividend

1.1

1.1

908

897

Final dividend (prior year)

2.2

2.2

1,816

1,794

Special dividend (prior year)

5.2

-

4,292

-

 

8.5

3.3

7,016

2,691

 

 

 

 

 

Proposed but not recognised as a liability:

 

 

 

 

Final dividend (current year)

2.2

2.2

1,639

1,816

Special dividend (current year)

-

5.2

-

4,292

 

2.2

7.4

1,639

6,108

 

The proposed final dividend was approved by the Board on 25 February 2014 but was not included as a liability as at 31 December 2013, in accordance with IAS 10 'Events after the Balance Sheet date'. If approved by shareholders at the Annual General Meeting the proposed final dividend will be payable on 27 May 2014 to shareholders on the register at the close of business on 25 April 2014.

 

5. Trade and other receivables

 

 

31 Dec 2013

31 Dec 2012

 

£000

£000

Trade receivables

4,286

2,411

Less: provision for impairment of receivables

(60)

(61)

Trade receivables - net

4,226

2,350

Other receivables

101

139

Prepayments and accrued income

722

674

 

5,049

3,163

 

6. Trade and other payables

 

 

31 Dec 2013

31 Dec 2012

 

£000

£000

Trade payables

532

368

Other tax and social security payable

991

658

Other payables

55

657

Accruals

1,259

1,877

Deferred income

15,349

14,285

 

18,186

17,845

 

7. Financial liabilities

 

 

 

31 Dec 2013

 

 

£000

Bank Loan

 

19,250

The borrowings are repayable as follows:

 

 

Within one year

 

3,000

In the second year

 

3,000

In the third to fifth years inclusive

 

13,250

 

 

19,250

Less: Amount due for settlement within 12 months (shown under current liabilities)

 

(3,000)

Amount due for settlement after 12 months

 

16,250

 

On 28 October 2013 Microgen Financial Systems Limited, a wholly owned subsidiary of Microgen plc, entered into a loan agreement with Royal Bank of Scotland plc for £20,000,000. The loan is secured solely against the assets of the Financial Systems operating business of the Group. Operating covenants are limited to the performance of the Financial Systems business only and are based on net debt leverage, interest cover and a minimum cash balance of £3,000,000 held within the Financial Systems business. In the event of a default of the loan, Microgen plc has the option, but not the obligation, to remedy. The loan is repayable over five years with an annual capital repayment of £3,000,000 and a final repayment of £5,000,000 on the fifth anniversary of the loan agreement. The loan is denominated in Pound Sterling and carries interest at LIBOR plus 1.75%. The Group entered into an interest rate swap on 28 October 2013, effectively fixing the interest rate at 3.24% over the five year period.

 

8. Provisions for other liabilities and charges

 

 

Provisions

 

31 Dec 2013

31 Dec 2012

 

£000

£000

Group

 

 

At 1 January

298

242

Charged/ (credited) to income statement

13

(45)

Charged to property, plant and equipment

-

100

Foreign exchange

(9)

1

At 31 December

302

298

 

 

Provisions have been analysed between current and non-current as follows:

 

Provisions

 

31 Dec 2013

31 Dec 2012

 

£000

£000

Current

33

42

Non-current

269

256

 

302

298

 

9. Share capital

 

The movement in authorised and issued ordinary share capital of 5 pence each during the year is detailed below.

 

 

Authorised

Issued and fully paid

 

Number

Amount

Number

Amount

 

 

£000

 

£000

At 1 January 2013

145,000,000

7,250

81,581,850

4,078

Issued under share option schemes

-

-

1,046,727

52

Share tender offer

 

 

(8,130,075)

(406)

At 31 December 2013

145,000,000

7,250

74,498,502

3,724

 

In the year the Company repurchased 8,130,075 ordinary shares for a consideration of £10,000,000 via a tender offer. The shares were subsequently cancelled.

10. Notes to the Group Cash Flow Statement

 

Reconciliation of profit for the year to net cash generated from operations

 

 

Year ended

31 Dec 2013

Year ended

31 Dec 2012

 

£000

£000

Profit before tax

8,688

9,187

Adjustments for:

 

 

Depreciation

790

788

Loss on disposal of fixed assets

9

-

Amortisation of intangible assets

-

118

Share-based payment expense

157

61

Finance income

(119)

(174)

Finance costs

119

-

 

 

 

Changes in working capital:

 

 

(Increase)/ decrease in receivables

(1,886)

2,448

Increase/ (decrease) in payables

341

(2,136)

Increase in provisions

4

56

 

 

 

Cash generated from operations

8,103

10,348

 

11. Statement by the directors

 

The preliminary results for the year ended 31 December 2013 and the results for the year ended 31 December 2012 are prepared under International Financial Reporting Standards as adopted for use in the EU ("IFRS"). The accounting policies adopted in this preliminary announcement are consistent with the Annual Report for the year ended 31 December 2012.

 

The financial information set out in this preliminary announcement does not constitute the Company's statutory accounts for the years ended 31 December 2013 or 31 December 2012. The financial information for the year ended 31 December 2012 is derived from the Annual Report delivered to the Registrar of Companies. The Annual Report for 2013 will be delivered to the Registrar of Companies in due course. The auditors' report on those accounts was unqualified and neither drew attention to any matters by way of emphasis nor contained a statement under either section 498(2) of Companies Act 2006 (accounting records or returns inadequate or accounts not agreeing with records and returns), or section 498(3) of Companies Act 2006 (failure to obtain necessary information and explanations).

 

The Board of Microgen approved the release of this audited preliminary announcement on 25 February 2014.

 

The Annual Report for the year ended 31 December 2013 will be posted to shareholders in due course and will be delivered to the Registrar of Companies following the Annual General Meeting of the Company. The report will also be available on the investor relations page of our web site (www.microgen.com). Further copies will be available on request and free of charge from the Company Secretary at Old Change House, 128 Queen Victoria Street, London, EC4V 4BJ.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR UVONRSRAUUAR
Date   Source Headline
3rd May 20247:00 amRNSTransaction in Own Shares
1st May 20244:10 pmRNSTotal Voting Rights
30th Apr 20244:46 pmRNSGrant of awards under 2020 Deferred Bonus Plan
29th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSNotice of 2024 Annual General Meeting
8th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20241:46 pmRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:01 amRNSAptitude to Accelerate Autonomous Finance
21st Mar 20247:01 amRNSShare buyback programme
21st Mar 20247:00 amRNSAudited Results for Year Ended 31 December 2023
21st Feb 20247:00 amRNSChange of Broker Arrangements
9th Feb 20247:00 amRNSHolding(s) in Company
31st Jan 20247:00 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSFull Year Trading Update and Notice of Results
4th Jan 20247:00 amRNSFynapse Win
30th Nov 20237:00 amRNSAppointment of Chief Executive Officer
12th Oct 20237:00 amRNSHolding(s) in Company
2nd Oct 20232:17 pmRNSGrant of awards
29th Sep 20237:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
21st Sep 20232:28 pmRNSHolding(s) in Company
20th Sep 20239:32 amRNSHolding(s) in Company
7th Sep 202310:15 amRNSGrant of Awards under Performance Share Plan
23rd Aug 20231:21 pmRNSHolding(s) in Company
23rd Aug 20231:15 pmRNSHolding(s) in Company
28th Jul 202312:18 pmRNSHolding(s) in Company
28th Jul 20237:00 amRNSHolding(s) in Company
27th Jul 20231:52 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSInterim Results
24th Jul 20235:22 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSHolding(s) in Company
19th Jul 20237:00 amRNSDirector Retirement
13th Jul 20237:00 amRNSTrading Update and Directorate Changes
23rd Jun 20234:43 pmRNSHolding(s) in Company
16th Jun 20234:22 pmRNSHolding(s) in Company
25th May 20235:22 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.